Cipla has received an order from US court, ruling that sales of its animal healthcare product allegedly infringed a patent held by Merial. The sales of the PetArmor Plus have been suspended in the US. The company is in process of filling appeal against the order.
The company’s net profit for the quarter ended March 31, 2011 has declined by 22.33% at Rs 214.00 crore as compared to Rs 275.53 crore for the quarter ended March 31, 2010. Its total income has increased by 19% to Rs 1689.55 crore for the quarter under review from Rs 1419.77 crore in the corresponding previous quarter.
